CoChat

Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome

Open access
Olbjørn, Christine, Cvancarova Småstuen, Milada, Thiis-Evensen, Espen, Nakstad, Britt, Vatn, Morten Harald, Jahnsen, Jørgen, Ricanek, Petr, Vatn, Simen, Moen, Aina EF, Tannæs, Tone M, Lindstrøm, Jonas C, Söderholm, Johan D, Halfvarson, Jonas, Gomollón, Fernando, Casén, Christina, Karlsson, Magdalena K, Kalla, Rahul, Adams, Alex T, Satsangi, Jack, Perminow, Gøri · 2019 · Clinical and Experimental Gastroenterology
Cited by 85

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal symptoms and healthy children, its relation to IBD subgroups, and treatment outcomes. Patients and methods: Fecal samples were collected from 235 children below 18 years of age. Eighty children had Crohn’s disease (CD), 27 ulcerative colitis (UC), 3 IBD unclassified, 50 were non-IBD symptomatic patients, and 75 were healthy. The bacterial abundance of 54 predefined DNA markers was measured with a 16S rRNA DNA-based test using GA-Map™ technology at diagnosis and after therapy in IBD patients. Results: Bacterial abundance was similarly reduced in IBD and non-IBD patients in 51 of 54 markers compared to healthy patients ( P <0.001). Only Prevotella was more abundant in patients ( P <0.01). IBD patients with ileocolitis or total colitis had more Ruminococcus gnavus ( P =0.02) than patients with colonic CD or left-sided UC. CD patients with upper gastrointestinal manifestations had higher Veillonella abundance ( P <0.01). IBD patients (58%) who received biologic therapy had lower baseline Firmicutes and Mycoplasma hominis abundance ( P <0.01) than conventionally treated. High Proteobacteria abundance was associated with stricturing/penetrating CD, surgery ( P <0.01), and nonmucosal healing ( P <0.03). Low Faecalibacterium prausnitzii abundance was associated with prior antibiotic therapy ( P =0.001), surgery ( P =0.02), and nonmucosal healing ( P <0.03). After therapy, IBD patients had unchanged dysbiosis. Conclusion: Fecal microbiota profiles differentiated IBD and non-IBD symptomatic children from healthy children, but displayed similar dysbiosis in IBD and non-IBD symptomatic patients. Pretreatment fecal microbiota profiles may be of prognostic value and aid in treatment individualization in pediatric IBD as severe dysbiosis was associated with an extensive, complicated phenotype, biologic therapy, and nonmucosal healing. The dysbiosis persisted after therapy, regardless of treatments and mucosal healing. Keywords: dysbiosis, Crohn’s disease, ulcerative colitis, Proteobacteria, biologic therapy, Faecalibacterium prausnitzii

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ceg.s186235

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 85

Metadata

Authors
Olbjørn, C., Cvancarova Småstuen, M., Thiis-Evensen, E., Nakstad, B., Vatn, M. H., Jahnsen, J., Ricanek, P., Vatn, S., Moen, A. E., Tannæs, T. M., Lindstrøm, J. C., Söderholm, J. D., Halfvarson, J., Gomollón, F., Casén, C., Karlsson, M. K., Kalla, R., Adams, A. T., Satsangi, J., & Perminow, G.
Venue
Clinical and Experimental Gastroenterology
Published
2019-01
Volume
Volume 12
Pages
37-49
ISSN
1178-7023 (ISSN-L)
OpenAlex
W2913282449
Cited by
85
References
14
FWCI
3.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.